Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report issued on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $32.00 target price on the stock.

A number of other equities research analysts also recently commented on the stock. Raymond James Financial upgraded shares of Compass Therapeutics to an “outperform” rating and set a $9.00 price objective for the company in a research report on Tuesday, July 1st. HC Wainwright restated a “buy” rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 21st. Finally, Guggenheim raised their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $12.89.

Compass Therapeutics Stock Down 5.1%

NASDAQ CMPX opened at $3.17 on Tuesday. Compass Therapeutics has a 52-week low of $1.14 and a 52-week high of $4.08. The business’s 50-day moving average price is $2.76 and its 200 day moving average price is $2.50. The firm has a market cap of $438.35 million, a P/E ratio of -7.04 and a beta of 1.49.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning acquired a new stake in shares of Compass Therapeutics during the 2nd quarter valued at approximately $30,000. Tower Research Capital LLC TRC lifted its position in shares of Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after acquiring an additional 12,917 shares during the period. Strs Ohio acquired a new stake in shares of Compass Therapeutics during the 1st quarter valued at approximately $34,000. BNP Paribas Financial Markets acquired a new stake in shares of Compass Therapeutics during the 4th quarter valued at approximately $27,000. Finally, Mariner LLC acquired a new stake in shares of Compass Therapeutics during the 4th quarter valued at approximately $30,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.